RT Journal Article
SR Electronic
T1 Suppressive myeloid cells are a hallmark of severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.03.20119818
DO 10.1101/2020.06.03.20119818
A1 Jonas Schulte-Schrepping
A1 Nico Reusch
A1 Daniela Paclik
A1 Kevin Baßler
A1 Stephan Schlickeiser
A1 Bowen Zhang
A1 Benjamin Krämer
A1 Tobias Krammer
A1 Sophia Brumhard
A1 Lorenzo Bonaguro
A1 Elena De Domenico
A1 Daniel Wendisch
A1 Martin Grasshoff
A1 Theodore S. Kapellos
A1 Michael Beckstette
A1 Tal Pecht
A1 Adem Saglam
A1 Oliver Dietrich
A1 Henrik E. Mei
A1 Axel R. Schulz
A1 Claudia Conrad
A1 Désirée Kunkel
A1 Ehsan Vafadarnejad
A1 Cheng-Jian Xu
A1 Arik Horne
A1 Miriam Herbert
A1 Anna Drews
A1 Charlotte Thibeault
A1 Moritz Pfeiffer
A1 Stefan Hippenstiel
A1 Andreas Hocke
A1 Holger Müller-Redetzky
A1 Katrin-Moira Heim
A1 Felix Machleidt
A1 Alexander Uhrig
A1 Laure Bousquillon de Jarcy
A1 Linda Jürgens
A1 Miriam Stegemann
A1 Christoph R. Glösenkamp
A1 Hans-Dieter Volk
A1 Christine Goffinet
A1 Jan Raabe
A1 Kim Melanie Kaiser
A1 Michael To Vinh
A1 Gereon Rieke
A1 Christian Meisel
A1 Thomas Ulas
A1 Matthias Becker
A1 Robert Geffers
A1 Martin Witzenrath
A1 Christian Drosten
A1 Norbert Suttorp
A1 Christof von Kalle
A1 Florian Kurth
A1 Kristian Händler
A1 Joachim L. Schultze
A1 Anna C Aschenbrenner
A1 Yang Li
A1 Jacob Nattermann
A1 Birgit Sawitzki
A1 Antoine-Emmanuel Saliba
A1 Leif Erik Sander
A1 Deutsche COVID-19 OMICS Initiative (DeCOI)
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.06.03.20119818.abstract
AB ‘Severe Acute Respiratory Syndrome - Coronavirus-2’ (SARS-CoV-2) infection causes Coronavirus Disease 2019 (COVID-19), a mild to moderate respiratory tract infection in the majority of patients. A subset of patients, however, progresses to severe disease and respiratory failure with acute respiratory distress syndrome (ARDS). Severe COVID-19 has been associated with increased neutrophil counts and dysregulated immune responses. The mechanisms of protective immunity in mild forms and the pathogenesis of dysregulated inflammation in severe courses of COVID-19 remain largely unclear. Here, we combined two single-cell RNA-sequencing technologies and single-cell proteomics in whole blood and peripheral blood mononuclear cells (PBMC) to determine changes in immune cell composition and activation in two independent dual-center patient cohorts (n=46+n=54 COVID-19 samples), each with mild and severe cases of COVID-19. We observed a specific increase of HLA-DRhiCD11chi inflammatory monocytes that displayed a strong interferon (IFN)-stimulated gene signature in patients with mild COVID-19, which was absent in severe disease. Instead, we found evidence of emergency myelopoiesis, marked by the occurrence of immunosuppressive pre-neutrophils and immature neutrophils and populations of dysfunctional and suppressive mature neutrophils, as well as suppressive HLA-DRto monocytes in severe COVID-19. Our study provides detailed insights into systemic immune response to SARS-CoV-2 infection and it reveals profound alterations in the peripheral myeloid cell compartment associated with severe courses of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Research Foundation (DFG, SFB-TR84 #114933180 to L.E.S., S.H., A.H., N.S., C.D.; INST 37/1049-1, INST 216/981-1, INST 257/605-1, INST 269/768-1 and INST 217/988-1, INST 217/577-1 to J.L.S; SFB TR57, SPP1937 to J.N.; GRK2157 to A.-E.S., ME 3644/5-1 to H.E.M.); the Berlin University Alliance (BUA, PreEP-Corona grant to L.E.S., V.C. and C.D.), the Berlin Institute of Health (BIH, grant to L.E.S., A.H., C.D.); the HGF grant sparse2big, the EU projects SYSCID (grant number 733100), and ERA CVD (grant number 00160389) to J.L.S.; the DZIF (TTU 04.816, 04.817 to J.N.); the Hector-Foundation (M89 to J.N.); the EU projects ONE STUDY (grant number 260687 to B.S.), BIO-DrIM (305147 to B.S.) and INsTRuCT (grant number 860003 to B.S.), the German Federal Ministry of Education and Research (BMBF, project RAPID to C.D., S.H., A.H.), and a Charite 3R project to B.S. and S.H.; Radboud University Medical Centre Hypatia Grant (2018 to Y.L.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review board of Charité (EA2/066/20)and the Institutional Review board of the University Hospital Bonn (073/19 and 134/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are deposited at the European Genome-phenome Archive (EGA) under access number EGAS00001004450, which is hosted by the EBI and the CRG.